PNC Financial Services Group Inc. lowered its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 318,588 shares of the financial services provider’s stock after selling 6,394 shares during the quarter. PNC Financial Services Group Inc. owned 0.67% of iShares Biotechnology ETF worth $53,794,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also bought and sold shares of IBB. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the 2nd quarter valued at about $25,000. Basepoint Wealth LLC purchased a new position in iShares Biotechnology ETF in the fourth quarter worth about $26,000. Cary Street Partners Financial LLC bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $29,000. Copia Wealth Management bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $34,000. Finally, Caitlin John LLC bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $34,000. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of IBB stock opened at $188.98 on Friday. iShares Biotechnology ETF has a 1 year low of $130.25 and a 1 year high of $199.05. The stock’s 50 day simple moving average is $179.10 and its two-hundred day simple moving average is $173.95.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
